https://www.scmp.com/rss/524293/feed The latest news and top stories on Demis Hassabis. A British artificial intelligence researcher and entrepreneur, he co-founded DeepMind, acquired by Google, and now leads Google DeepMind. His responsibilities include pioneering AI breakthroughs like AlphaGo and AlphaFold, the latter earning him the 2024 Nobel Prize in Chemistry for solving protein structure prediction. Hassabis, also a UK Government AI Adviser and founder of Isomorphic Labs, has a background in cognitive neuroscience and game... en https://assets.i-scmp.com/static/img/icons/scmp-meta-1200x630.png https://www.scmp.com Wency Chen Wency Chen Baidu on Thursday unveiled Ernie 5.0, a multimodal artificial intelligence model with 2.4 trillion parameters, as use of the Chinese tech giant’s AI-powered namesake assistant climbed to 200 million monthly active users. The omni-modal foundation model, capable of processing text, images, audio and video, is the Beijing-based company’s most advanced to date. The model was first previewed in November and has since climbed the rankings. A leaderboard published last week by LMArena showed... https://www.scmp.com/tech/tech-trends/article/3340866/baidu-launches-ernie-50-firms-ai-assistant-users-reach-200-million-month?utm_source=rss_feed https://www.scmp.com/tech/tech-trends/article/3340866/baidu-launches-ernie-50-firms-ai-assistant-users-reach-200-million-month?utm_source=rss_feed Thu, 22 Jan 2026 12:30:15 +0000 Eunice Xu Eunice Xu Hangzhou-based biotech start-up MindRank has progressed to Phase 3 clinical trials for its weight-loss drug, making it China’s first artificial intelligence-assisted Category 1 new drug to reach this stage. MindRank announced last month that it had initiated a Phase 3 clinical trial in China for MDR-001, a small molecule GLP-1 receptor agonists designed with the help of AI. GLP-1 receptor agonists mimic natural hormones to regulate blood sugar and appetite. According to Niu Zhangming, MindRank’s... https://www.scmp.com/tech/tech-trends/article/3338618/mindrank-phase-3-trial-chinas-first-ai-assisted-new-drug-cutting-rd-costs-60?utm_source=rss_feed https://www.scmp.com/tech/tech-trends/article/3338618/mindrank-phase-3-trial-chinas-first-ai-assisted-new-drug-cutting-rd-costs-60?utm_source=rss_feed Sun, 04 Jan 2026 02:00:16 +0000 Bloomberg Bloomberg Microsoft pledged to invest US$17.5 billion on artificial intelligence and cloud computing in India over four years, targeting the world’s most populous nation to help fuel its growth. Chief Executive Officer Satya Nadella made the announcement Tuesday after meeting with Prime Minister Narendra Modi in New Delhi, ahead of a tour through the country. Microsoft said the investment will focus on three pillars – scale, skills and sovereignty – which align with Modi’s goal of building a broad... https://www.scmp.com/tech/big-tech/article/3335847/microsoft-makes-us175-billion-pledge-ai-cloud-india?utm_source=rss_feed https://www.scmp.com/tech/big-tech/article/3335847/microsoft-makes-us175-billion-pledge-ai-cloud-india?utm_source=rss_feed Wed, 10 Dec 2025 04:03:04 +0000 Agence France-Presse Agence France-Presse Artificial intelligence, the technology upending nearly every corner of society, is creeping into religion, serving up virtual Jesuses and automated sermons – a change drawing mixed reviews from the faithful. Religious chatbots and other faith-based digital tools are growing in number, offering counsel, comfort and spiritual guidance during an age of rapidly transforming socialisation and engagement. One app, called Text With Jesus, has thousands of paying subscribers. It lets people ostensibly... https://www.scmp.com/lifestyle/article/3328080/ai-chatbots-religious-apps-offer-spiritual-guidance-posing-jesus-and-other-figures?utm_source=rss_feed https://www.scmp.com/lifestyle/article/3328080/ai-chatbots-religious-apps-offer-spiritual-guidance-posing-jesus-and-other-figures?utm_source=rss_feed Tue, 07 Oct 2025 04:38:48 +0000 Eric Ng,Xinmei Shen Eric Ng,Xinmei Shen Chinese biotech companies are winning deals with global giants as they spearhead the race to deploy artificial intelligence (AI) in the search for new and effective drugs. In the past five months alone, British drug maker AstraZeneca, US rival Pfizer and biotech firm DoveTree Medicines have signed deals potentially worth a combined US$22 billion with four China-based companies using AI-assisted drug discovery. Three of the Chinese businesses are listed on the Hong Kong stock market. China’s... https://www.scmp.com/plus/article/3324862/ai-turns-china-biotechs-drug-discovery-leaders?utm_source=rss_feed https://www.scmp.com/plus/article/3324862/ai-turns-china-biotechs-drug-discovery-leaders?utm_source=rss_feed Tue, 09 Sep 2025 07:00:13 +0000